Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules

@inproceedings{Luo2015LeukemiaIF,
  title={Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules},
  author={Qin Luo and Yurong Zhang and Ning Wang and Guangzhi Jin and Haojie Jin and Dishui Gu and Xuemei Tao and Xisong Huo and Tianxiang Ge and Wen-Ming Cong and Cun Wang and Wenxin Qin},
  booktitle={Oncotarget},
  year={2015}
}
Differential diagnosis of well-differentiated hepatocellular carcinoma (WD-HCC) and high-grade dysplastic nodules (HGDNs) represents a challenge for pathologists. Several immunohistochemistry markers have been identified to distinguish hepatocellular carcinoma (HCC) from HGDNs. However, sensitivity or specificity of the individual marker is still limited. In this study, we analyzed dynamic alteration of leukemia inhibitory factor receptor (LIFR) and CD34 during hepatocarcinogenesis from… CONTINUE READING